First Dallas Securities Inc. Reduces Stock Position in Johnson & Johnson (NYSE:JNJ)

First Dallas Securities Inc. reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,033 shares of the company’s stock after selling 461 shares during the period. First Dallas Securities Inc.’s holdings in Johnson & Johnson were worth $1,740,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. AMF Tjanstepension AB grew its holdings in Johnson & Johnson by 14.2% in the 3rd quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock valued at $68,985,000 after buying an additional 52,997 shares during the period. Alpha Financial Partners LLC acquired a new stake in shares of Johnson & Johnson in the third quarter worth approximately $209,000. Brookstone Capital Management grew its holdings in Johnson & Johnson by 5.5% in the third quarter. Brookstone Capital Management now owns 73,811 shares of the company’s stock valued at $11,962,000 after purchasing an additional 3,842 shares during the period. Strategic Wealth Partners Ltd. raised its stake in Johnson & Johnson by 2.0% during the third quarter. Strategic Wealth Partners Ltd. now owns 6,401 shares of the company’s stock worth $1,037,000 after purchasing an additional 128 shares during the period. Finally, Brightwater Advisory LLC boosted its holdings in shares of Johnson & Johnson by 3.4% in the 3rd quarter. Brightwater Advisory LLC now owns 3,713 shares of the company’s stock valued at $602,000 after purchasing an additional 122 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction dated Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ? increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Trading Down 0.8 %

NYSE JNJ opened at $153.46 on Friday. The company’s fifty day moving average price is $147.49 and its two-hundred day moving average price is $156.08. The company has a market capitalization of $369.47 billion, a price-to-earnings ratio of 23.08, a price-to-earnings-growth ratio of 2.44 and a beta of 0.52. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The firm had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same period in the previous year, the company earned $2.29 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.3% on a year-over-year basis. As a group, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.23%. Johnson & Johnson’s payout ratio is 74.59%.

Analyst Upgrades and Downgrades

JNJ has been the topic of several research reports. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Citigroup decreased their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Bank of America decreased their price objective on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research note on Thursday, January 23rd. Guggenheim upped their price target on shares of Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a research report on Monday. Finally, Wells Fargo & Company cut their price objective on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $170.67.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.